Business Insider
My Markets Watchlist
Markets Stocks

Moderna Inc Stock , MRNA

28.15 +0.02 +0.07%
10:12:59 AM BTT
News Analyst Data Analyst Opinions Insider Activity Dividend Calendar

On Tuesday morning 06/10/2025 the Moderna Inc share started trading at the price of $27.97. Compared to the closing price on Monday 06/09/2025 on BTT of $28.13, this is a drop of 0.57%. There are 386.74 M shares outstanding in Moderna Inc, which values the company at $8.96 B.
Is Moderna stock a Buy, Sell or Hold? Moderna stock hasn't recieved a clear consensus rating. The average rating score is and is based on 18 buy ratings, 18 hold ratings, and 6 sell ratings.
What was the 52-week low for Moderna stock? The low in the last 52 weeks of Moderna stock was 23.16. According to the current price, Moderna is 121.18% away from the 52-week low.
What was the 52-week high for Moderna stock? The high in the last 52 weeks of Moderna stock was 153.26. According to the current price, Moderna is 18.31% away from the 52-week high.
What are analysts forecasts for Moderna stock? The 42 analysts offering price forecasts for Moderna have a median target of 105.48, with a high estimate of 231.00 and a low estimate of 26.00. The median estimate represents a 26.60 difference from the last price of 28.06.

Moderna Stock Snapshot

28.14
Bid
30.00
Bid Size
28.17
Ask
100.00
Ask Size
6/10/2025
Date
10:12 AM
Time
95,540.00
Volume
28.13
Prev. Close
27.97
Open
10.89 B
Market Cap in USD
386.74 M
Number of Shares
386.74 M
Total Number of Shares
27.35
Day Low
28.24
Day High
28.15
23.16
52 Week Low
153.26
52 Week High
28.15
0.00
Dividend in USD
0.00
Dividend Yield
88.56
Free Float in %
-9.28
EPS in USD
28.24
Book Value per Share in USD
-7.82
Cash Flow per Share in USD

Historical Prices for Moderna

Loading..
Date Open Close Daily High Daily Low
Price change over selected period: 0% 0

Moderna Analyst Data

Total Analysts: 42
Buy Ratings: 18 Neutral Ratings: 18 Sell Ratings: 6
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price *Price Target
Lowest: 26.00 Median: 105.48 Highest: 231.00
*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.

Moderna Analyst Opinions

  • All
  • Buy
  • Hold
  • Sell
Date Analyst Rating Price
05/22/25 J.P. Morgan
Maintained Sell $26
05/02/25 UBS
Maintained Buy $70
05/02/25 Barclays Capital
Maintained Hold $40
05/02/25 RBC Capital Markets
Maintained Hold $28
05/02/25 Evercore
Maintained Hold $32
04/09/25 Morgan Stanley
Maintained Hold $32
03/21/25 J.P. Morgan
Maintained Sell $33
03/13/25 Citigroup Corp.
Maintained Hold $40
02/19/25 UBS
Maintained Buy $78
02/18/25 RBC Capital Markets
Maintained Hold $40
02/18/25 Barclays Capital
Downgraded to Hold $45
02/11/25 Bank of America Merrill Lynch
Maintained Sell $34
01/28/25 Goldman Sachs
Maintained Buy $99
01/27/25 Evercore
Maintained Hold $50
06/28/24 Needham & Company, LLC
Maintained Hold
06/27/24 Piper Sandler
Maintained Buy $214
06/27/24 Evercore
Maintained Hold $120
06/12/24 Oppenheimer & Co. Inc.
Maintained Buy $179
06/03/24 RBC Capital Markets
Maintained Buy $160
06/03/24 Needham & Company, LLC
Maintained Hold
05/14/24 Evercore
Maintained Hold $120
05/07/24 UBS
Maintained Buy $151
05/03/24 Capital Depesche
Maintained Hold $106
05/03/24 RBC Capital Markets
Maintained Buy $135
05/03/24 Oppenheimer & Co. Inc.
Maintained Buy $163
05/02/24 Needham & Company, LLC
Maintained Hold
04/11/24 Needham & Company, LLC
Maintained Hold
04/09/24 Jefferies & Company Inc.
Maintained Buy $125
03/28/24 RBC Capital Markets
Maintained Buy $125
03/28/24 Needham & Company, LLC
Maintained Hold
02/26/24 HSBC
Downgraded to Sell $86
02/23/24 RBC Capital Markets
Maintained Buy $125
02/23/24 Capital Depesche
Maintained Hold $91
01/02/24 Oppenheimer & Co. Inc.
Upgraded to Buy $142
12/01/23 J.P. Morgan
Maintained Hold $90
11/29/23 Capital Depesche
Maintained Hold $82
11/03/23 RBC Capital Markets
Maintained Buy $125
11/03/23 Goldman Sachs
Maintained Buy $231
11/03/23 HSBC
Upgraded to Sell $69
11/02/23 Deutsche Bank
Downgraded to Sell
09/13/23 Argus Research Company
Maintained Buy $140
08/04/23 Morgan Stanley
Maintained Hold $123
08/04/23 Bank of America Merrill Lynch
Maintained Hold $150
08/04/23 RBC Capital Markets
Maintained Buy $190
08/03/23 Deutsche Bank
Downgraded to Hold $125
07/24/23 William Blair
Maintained Hold
07/14/23 HSBC
Maintained Sell $97
07/11/23 Morgan Stanley
Maintained Hold $128
06/26/23 UBS
Upgraded to Buy $191

Moderna Estimates* in USD

  2025 2026 2027 2028 2029
Revenue 2,055 2,378 2,978 4,154 7,021
Dividend 0.00 0.00 0.00 0.00 -
Dividend Yield (in %) 0.00 % 0.00 % 0.00 % 0.00 % -
EPS -10.06 -7.45 -4.59 -2.74 0.84
P/E Ratio -2.80 -3.78 -6.13 -10.25 33.46
EBIT -4,154 -3,070 -1,921 -1,041 526
EBITDA -3,895 -3,006 -1,919 -664 -
Net Profit -3,906 -2,921 -1,855 -1,105 513
Net Profit Adjusted -3,956 -3,132 -2,137 -1,412 -1,389
Pre-Tax Profit -3,927 -2,946 -1,858 -925 1,272
Pre-Tax Profit Reported -4,073 -3,024 -2,013 -1,566 -1,020
EPS (Non-GAAP) ex. SOE -10.29 -7.80 -5.36 -3.01 -2.59
EPS (GAAP) -10.03 -7.64 -5.03 -3.82 -3.11
Gross Income 919 1,506 1,883 2,697 5,214
Cash Flow from Investing 2,971 1,084 531 -9 -292
Cash Flow from Operations -3,163 -2,729 -1,958 -1,631 -1,175
Cash Flow from Financing 1 0 1,000 500 500
Cash Flow per Share -8.87 -5.73 -3.03 3.02 19.77
Free Cash Flow -3,592 -2,637 -1,667 -921 -812
Free Cash Flow per Share -7.24 -3.95 -1.63 8.01 15.44
Book Value per Share 20.37 12.59 7.18 2.31 -
Net Debt -4,184 -2,151 -734 -329 1,335
Research & Development Exp. 3,978 3,448 2,903 2,921 2,902
Capital Expenditure 380 302 251 292 295
Selling, General & Admin. Exp. 1,074 1,023 1,004 1,082 1,658
Shareholder’s Equity 7,653 5,363 3,841 4,024 5,910
Total Assets 11,160 9,246 8,125 8,218 9,520
  Previous Quarter
ending 03/31/25 		Current Quarter
ending 06/30/25 		Next Quarter
ending 09/30/25 		Current Year
ending 12/31/25 		Next Year
ending 12/31/26
Earnings Estimates
No. of Analysts - 16 16 24 24
Average Estimate - -2.957 USD -1.805 USD -10.056 USD -7.451 USD
Year Ago - -3.331 USD 0.034 USD -9.273 USD -
Publish Date - 7/31/2025 10/30/2025 - -
Revenue Estimates
No. of Analysts - 14 14 22 22
Average Estimate - 117 USD 1,142 USD 2,055 USD 2,378 USD
Year Ago - 241 USD 1,862 USD 3,236 USD -
Publish Date - 7/31/2025 10/30/2025 - -
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet

Income Statements in Mio. USD

2024 2023 2022 2021 2020 2019 2018
Sales 3,236.00 6,840.00 19,109.00 18,413.00 803.40 60.21 135.07
Change of sales in % -52.69 -64.21 3.78 2,191.90 1,234.34 -55.42 -34.38
Gross profit on sales 1,583.00 1,526.00 13,345.00 15,564.00 764.21 29.19 110.21
Gross profit on sales change in % 3.74 -88.57 -14.26 1,936.61 2,518.24 -73.52 -40.52
Operating income -3,945.00 -4,247.00 9,266.00 13,238.00 -763.14 -545.72 -468.87
Operating income change in % 7.11 - -30.00 - -39.84 -16.39 -74.07
Income before tax -3,607.00 -3,942.00 9,575.00 13,285.00 -744.51 -514.72 -440.01
Income before tax change in % 8.50 - -27.93 - -44.65 -16.98 -71.88
Income after tax -3,561.00 -4,714.00 8,362.00 12,202.00 -747.06 -514.02 -388.86
Income after tax change in % 24.46 - -31.47 - -45.34 -32.19 -51.95

Balance Sheet in Mio. USD

2024 2023 2022 2021 2020 2019 2018
Total liabilities 3,241.00 4,572.00 6,964.00 10,724.00 4,775.38 414.61 431.91
Long-term liabilities per share 2.68 4.08 5.30 3.96 0.97 0.81 0.64
Equity 10,901.00 13,854.00 19,123.00 14,145.00 2,561.38 1,174.81 1,530.24
Equity change in % -21.32 -27.55 35.19 452.24 118.02 -23.23 -
Balance sheet total 14,142.00 18,426.00 26,087.00 24,869.00 7,336.75 1,589.42 1,962.15
Balance sheet total change in % -23.25 -29.37 4.90 238.96 361.60 -19.00 80.93

Key Data in USD

2024 2023 2022 2021 2020 2019 2018
Sales per share 8.43 17.91 45.94 42.72 2.11 0.18 1.67
P/E ratio (year end quote, basic EPS) - - 8.94 8.97 - - -
P/E ratio (year end quote, diluted EPS) - - 8.94 8.97 - - -
Dividend yield in % 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Equity ratio in % 77.08 75.19 73.30 56.88 34.91 73.91 77.99
Debt ratio in % 22.92 24.81 26.70 43.12 65.09 26.09 22.01

Moderna Insider Activity

Name Date shares traded shares held Price type (sell/buy) option
Klinger Shannon Thyme 05/29/2025 113.00 26,300.00 26.93 Sell No
Hoge Stephen 05/29/2025 316.00 1,452,119.00 26.93 Sell No
Klinger Shannon Thyme 05/29/2025 233.00 26,413.00 n/a Buy No
Hoge Stephen 05/29/2025 652.00 1,452,435.00 n/a Buy No
Klinger Shannon Thyme 05/27/2025 159.00 26,180.00 26.76 Sell No
Hoge Stephen 05/27/2025 295.00 1,451,783.00 26.76 Sell No
Mock James M 05/27/2025 159.00 16,191.00 26.76 Sell No
Klinger Shannon Thyme 05/27/2025 328.00 26,339.00 n/a Buy No
Hoge Stephen 05/27/2025 610.00 1,452,078.00 n/a Buy No
Mock James M 05/27/2025 328.00 16,350.00 n/a Buy No
Klinger Shannon Thyme 05/26/2025 374.00 26,011.00 26.26 Sell No
Hoge Stephen 05/26/2025 695.00 1,451,468.00 26.26 Sell No
Mock James M 05/26/2025 374.00 16,022.00 26.26 Sell No
Klinger Shannon Thyme 05/26/2025 773.00 26,385.00 n/a Buy No
Hoge Stephen 05/26/2025 1,436.00 1,452,163.00 n/a Buy No
Mock James M 05/26/2025 773.00 16,396.00 n/a Buy No
Rubenstein David M. 04/29/2025 677.00 677.00 n/a Buy No
Hussain Abbas 04/29/2025 892.00 892.00 n/a Buy No
Horning Sandra 04/29/2025 979.00 2,352.00 n/a Buy No
NABEL ELIZABETH G 04/29/2025 979.00 3,084.00 n/a Buy No
Mock James M 04/03/2025 703.00 15,623.00 25.73 Sell No
Mock James M 04/03/2025 1,452.00 16,326.00 n/a Buy No
Klinger Shannon Thyme 03/06/2025 551.00 25,612.00 34.30 Sell No
Klinger Shannon Thyme 03/06/2025 1,139.00 26,163.00 n/a Buy No
Bancel Stephane 03/02/2025 102,821.00 9,153,193.00 31.04 Buy No

Moderna Dividend Calendar

Date Name Dividend *yield Currency
2024 Moderna Inc 0.00 0.00 USD
2023 Moderna Inc 0.00 0.00 USD
2022 Moderna Inc 0.00 0.00 USD
2021 Moderna Inc 0.00 0.00 USD
2020 Moderna Inc 0.00 0.00 USD
2019 Moderna Inc 0.00 0.00 USD
2018 Moderna Inc 0.00 0.00 USD
2017 Moderna Inc - - USD
2016 Moderna Inc - - USD
*Yield of the Respective Date

Moderna Calendar

Event Estimate Info Date
Earnings Report -2.958 USD Q2 2025 Earnings Release 07/31/2025
Earnings Report -1.805 USD Q3 2025 Earnings Release 10/30/2025
Earnings Report -2.742 USD Q4 2025 Earnings Release 02/19/2026
Earnings Report -2.422 USD Q1 2026 Earnings Release 04/30/2026

Moderna Past Events

Event Actual EPS Info Date
Earnings Report -2.520 USD Q1 2025 Earnings Release 05/01/2025
Annual General Meeting -9.280 USD Annual General Meeting 04/30/2025
Earnings Report -2.910 USD Q4 2024 Earnings Release 02/14/2025
Earnings Report 0.030 USD Q3 2024 Earnings Release 11/07/2024
Earnings Report -3.330 USD Q2 2024 Earnings Release 08/01/2024
Annual General Meeting -12.330 USD Annual General Meeting 05/06/2024
Earnings Report -3.070 USD Q1 2024 Earnings Release 05/02/2024
Earnings Report 0.550 USD Q4 2023 Earnings Release 02/22/2024
Earnings Report -9.530 USD Q3 2023 Earnings Release 11/02/2023
Earnings Report -3.620 USD Q2 2023 Earnings Release 08/03/2023
Earnings Report 0.190 USD Q1 2023 Earnings Release 05/04/2023
Annual General Meeting 20.120 USD Annual General Meeting 05/03/2023
Earnings Report 3.610 USD Q4 2022 Earnings Release 02/23/2023
Earnings Report 2.530 USD Q3 2022 Earnings Release 11/03/2022
Earnings Report 5.240 USD Q2 2022 Earnings Release 08/03/2022
Earnings Report 8.580 USD Q1 2022 Earnings Release 05/04/2022
Annual General Meeting 28.290 USD Annual General Meeting 04/28/2022
Earnings Report 11.290 USD Q4 2021 Earnings Release 02/24/2022

Moderna Profile

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr. , Derrick J.

Moody’s Daily Credit Risk Score

Risk
  • Low
  • Medium
  • High
5
Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’s balance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of credit risk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes into account day-to-day movements in market value compared to a company’s liability structure.

Moderna Management

Name Job
Noubar B. Afeyan Chairman
Kate Cronin Chief Brand Officer
Melanie Ivarsson Chief Development Officer
Stéphane Bancel Chief Executive Officer & Director
James M. Mock Chief Financial Officer
Jacqueline Miller Chief Medical Officer
Tracey Franklin Chief People & Digital Technology Officer
José M. Vega Chief Safety Officer
Jerh Collins Chief Technical Operations & Quality Officer
Jonathan Hoggatt Director-Hematology
Rose Loughlin Executive Vice President-Research
Sandra J. Horning Independent Director
Elizabeth G. Nabel Independent Director
Elizabeth E. Tallett Independent Director
Francois Nader Independent Director
David Mark Rubenstein Independent Director
Paul L. Sagan Independent Director
Shah Abbas Hussain Independent Director
Stephen Hoge President
Paula Hammond Scientific Advisory Board
Shannon Thyme Klinger Secretary & Chief Legal Officer
Lavina A. Talukdar Senior Vice President & Head-Investor Relations
Patrick Norman Bergstedt Senior Vice President-Commercial Vaccines
John Lepore Senior Vice President-Government Engagement
Charbel Haber Senior Vice President-Regulatory Science